In March 30th, Shan Dong Kexing Bioproducts Co.Ltd(688136) , a listed company of the Taizhou innovation and marketing board, signed the exclusive promotion service agreement of the Xidan market in the Chinese mainland market with the Mai Po pharmaceutical company, the Chinese mainland stock company, and Shan Dong Kexing Bioproducts Co.Ltd(688136) , which has gained exclusive promotion rights in mainland China.
It is understood that this is another in-depth cooperation after Shan Dong Kexing Bioproducts Co.Ltd(688136) won the exclusive commercial rights and interests of 32 overseas countries of mabteko infliximab last year.
According to the announcement, infliximab for injection is the first listed infliximab biological similar drug in China. It is mainly used for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, adult ulcerative colitis, adult and child Crohn’s disease and fistula Crohn’s disease. Its original drug lik is a specific blocking tumor necrosis factor (TNF) developed by Johnson & Johnson / MSD- α) Human mouse chimeric monoclonal antibody, which was first approved by FDA to be listed in the United States in 1998 and in Europe the following year, with a global sales peak of US $9.24 billion. According to Shan Dong Kexing Bioproducts Co.Ltd(688136) announcement, the results of clinical trials, non clinical comparative studies and pharmaceutical comparison studies show that letidine is equivalent to the original drug in terms of efficacy and safety. At present, the number of patients with approved indications in China exceeds 10 million, which continues to grow, and there is a huge long-term unmet market demand.
The announcement indicates that Shan Dong Kexing Bioproducts Co.Ltd(688136) will be able to gain exclusive promotion rights in Chinese mainland, which will help enrich the company’s product layout in the free domain, expand the commercial cooperation of the company in the field of self exemption, enhance the influence and competitiveness of the company, and expect to have a positive impact on the company’s future business performance.
According to the data of fiercepharma website, in 2020, the global sales of infliximab was US $4.195 billion, ranking among the top 20 in global drug sales. According to the statistics of Intranet, the sales volume of lik in public hospitals in the first half of 2021 was 550 million yuan, a year-on-year increase of 105%.
The company said that at present, the winning price of class stop is generally more than 1200 yuan, which has market competitiveness and will greatly promote Shan Dong Kexing Bioproducts Co.Ltd(688136) future revenue growth. At the same time, for biological similar drugs, the promotion ability of the marketing team is very important Shan Dong Kexing Bioproducts Co.Ltd(688136) has more than 20 years of commercialization experience, and its marketing network is all over the world Shan Dong Kexing Bioproducts Co.Ltd(688136) over the years, we have worked hard on the market, formed a stable market position and good brand advantages, and built a national three-dimensional marketing network, covering more than 18000 terminals across the country, including more than 6500 grade hospitals. It has achieved market access and sales in more than 30 countries around the world, such as Brazil, the Philippines and Indonesia. The market share of its four core products is among the best. According to the data, “sirokin” ranked first in the market share of Chinese short acting human interferon for injection in 2020, with a share of 30.81%, and “yipuding” ranked third in the market share of Chinese erythropoietin in 2020. Human granulocyte stimulating factor – batex and Clostridium butyricum – changlekang ranked in the forefront of China’s market share in 2020.
The cooperation agreement between taifumai Pharmaceutical Co., Ltd. and bofuhai Pharmaceutical Co., Ltd. has been approved by the State Administration of overseas medicine for 36 months, and the company has been registered in June 2021.
